seen from United States
seen from Canada
seen from Netherlands
seen from Italy
seen from Canada
seen from Australia
seen from Canada
seen from Canada
seen from Malaysia
seen from Italy
seen from India
seen from Malaysia
seen from Malaysia
seen from Brazil
seen from Chile
seen from Chile
seen from China
seen from France
seen from Netherlands
seen from Estonia
A Pot To Pee In
A Pot To Pee In
I started my second cycle of chemotherapy this morning with two hours of hydration, anti-nausea drugs, and gemcitabine. In order to qualify to receive the gemcitabine, I had to produce more urine. The nurses have been collecting my urine all day to insure I was fully hydrated. So don’t say to me, “You don’t have a pot to pee in!” Now rather cisplatin is dripping and I’ve been thinking about the…
View On WordPress
PEG Filgrastim use for Cancer Treatments, Cancer Medicine this pharmaceutical products available in - USV India Company.
Filgrastim
Common Brand Names: Neupogen
Therapeutic Class: A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes.
Common Injectable Dosage Forms:
Injection: 300 mcg/mL (1 mL, 1.6 mL), 600 mcg/mL (0.5 mL, 0.8 mL)
Dosage Ranges:
The recommended initial dose is 5 mcg/kg/day for up to 2 weeks or until the absolute neutrophil count reaches 10,000/mm3 for patients that are in post-antineoplastic therapy states.
In bone marrow transplantation, dosage is 10 mcg/kg/day and adjusted accordingly.
Administration and Stability: The commercially available solution (300 mcg/mL) may be given by direct rapid SQ injection. When given by IV infusion, the desired dose should be diluted with 50-100 mL of D5W to a concentration not less than 5 mcg/mL and may be given over 15-60 minutes or infused continuously over 24 hours. For continuous SQ infusion, the dose is diluted with 10-50 mL of D5W and administered at a rate not exceeding 10 mL/24 hours. When diluted to less than 15 mcg/mL, the solution should have 2 mcg/mL of albumin added to lessen the likelihood of adsorption. pH 4
Pharmacology/Pharmacokinetics: Filgrastim exerts its hematopoietic effects primarily by binding to neutrophil progenitor target cells that acts to stimulate proliferation of neutrophils within the bone marrow and possibly other sites. Following subcutaneous bolus administration, peak serum levels are observed in 2-6 hours. It is rapidly distributed with highest concentrations in the bone marrow, adrenal glands, kidney, and liver. The elimination half-life is 1.5-7 hours.
Drug and Lab Interactions: Filgrastim should not be administered within 24 hours before or after a dose of myelosuppressive antineoplastic agent. Because of transient decreases in platelet counts following filgrastim doses, caution should be used with patients on other platelet depressing agents. Lithium could theoretically potentiate the effects of filgrastim, but this has not been clinically established.
Contraindications/Precautions: Contraindicated in patients with known sensitivity to any proteins derived from E. coli. CBC and platelet counts should be performed prior to initiation and at least twice weekly during therapy to avoid the possibility of excessive leukocytosis or thrombocytopenia. Caution should be exercised in patients with suspected myeloid malignancies as tumor growth could be stimulated by filgrastim therapy. Pregnancy Category C.
Monitoring Parameters: CBC with diff., monitor for neutropenia.
Adverse Effects: The most common adverse effect is bone pain; other less common reactions include fever, elevations in serum uric acid, local cutaneous reactions, and occasionally, splenomegaly.
Common Clinical Applications: Effective in decreasing the incidence of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive therapy, and in reducing duration of neutropenia when undergoing myeloablative chemotherapy.
PEG Filgrastim use for Cancer Treatments, Cancer Medicine this pharmaceutical products available in - USV India Company.
PEG Filgrastim use for Cancer Treatments, Cancer Medicine this pharmaceutical products available in - USV India Company.
Always Have Hope
New Story has been published on https://enzaime.com/always-have-hope/
Always Have Hope
A few months ago, I thought it was the beginning of the end; I thought I was dying. My cancer had been spreading like wild fire through my weak and tired body for eight months. My oncologist told me my treatment options were becoming limited. How could I not think I was dying?
I never give up hope and I believe in miracles. My family and friends give me much love and support, which helps get through the rough times and celebrate the good times. I was so happy this week to share some good news, finally. I am not dying, at least for the time being.
Last Tuesday I received scans. Thursday, I met with Dr. M to discuss the scans and treatment. Dr. M came in the room with a big smile on her face. She said hello, shook Mark and my hands, and sat down. The first sentence out of her mouth was, “I am thilled with your scans.” All tumors, lesions, and lymph nodes have shrunk. My tumor markers have come down 90%…. WOW! Dr. M and I hugged with big smiles on our faces. Mark had a big smile on his face too.
I love receiving good news about my condition, but I always remain cautious. Some treatments last for a long time, some do not. I have experienced both sides of treatments. However, I am thrilled, and rejoicing at this wonderful news.
Eribulin, my chemotherapy, will be given every other week instead of two weeks on and one week off. My white and blood red blood counts go way down after receiving Eribulin and take more than a week to come up in order to receive chemo. This is because my bone marrow is tired from receiving so much chemotherapy. I will also be taking neupogen injections to help keep the white counts from getting too low.
As you might know, I try to look for the silver lining in everything. Right now the silver lining is weight loss! Between my thyroid, and cancer treatments starting in 2010, my weight fluctuated quite a bit. In March of this year, I lost my appetite. This continued until June before starting the Eribulin. I am happy to say my appetite has returned! I am content with my weight now. I needed a new wardrobe, and Michaela and I had a lot of fun shopping for new clothes… And we still are!
Thanks for reading my blog, and supporting me through the ups and the downs. This photo was taken a couple of weeks ago by the talented Paul Vicario. He, and the talented Dee Lewis have captured the “real me” through their beautiful photos.
Sahte Neupogen Reçetesi Soruşturması Hakkında
Sahte Neupogen Reçetesi Soruşturması Hakkında
Neupogen isimli ilaçtan dolayı SGK Cibali Sağlık Sosyal Güvenlik Merkezi’ne çağrılan üyelerimizin yaşadığı mağduriyeti Kurum yetkililerine iletmek ve yetkililerle görüşmek amacıyla […] İSTANBUL ECZACI ODASI http://www.ieo.org.tr/?page=Duyurular&anns_ID=5529
View On WordPress
My past year. 29 syringes and 32 needles.
